United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium lactate (unii: tu7hw0w0qt) (lactic acid - unii:33x04xa5at, sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (chloride ion - unii:q32zn48698, magnesium cation - unii:t6v3lhy838), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295 - dextrose monohydrate 5 g in 100 ml - 5% dextrose and electrolyte no. 48 injection (multiple electrolytes and dextrose injection, type 1, usp) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent. 5% dextrose and electrolyte no. 48 injection (multiple electrolytes and dextrose injection, type 1, usp) is contraindicated in patients

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient. none known.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient. none known. check flexible container solution composition, lot number, and expiry date. do not remove solution container from its overwrap until immediately before use. use sterile equipment and aseptic technique. to open - turn solution container over so that the text is face down. using the pre-cut corner tabs, peel open the overwrap and remove solution container. - check the solution container for leaks by squeezing firmly. if leaks are found, or if the seal is not intact, discard the solution. - do not use if the solution is cloudy or a precipitate is present. to add medication - identify white additive port with arrow pointing toward container. - immediately before injecting additives, break off white additive port cap with the arrow pointing toward container. - hold base of white additiv

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37) - 2.5% dextrose and 0.45% sodium chloride injection is indicated as a source of water, electrolytes and calories. 2.5% dextrose and 0.45% sodium chloride injection is contraindicated in patients with: - known hypersensitivity to dextrose and/or sodium chloride [see warnings and precautions 5.1)] - clinically significant hyperglycemia [see warnings and precautions (5.2)] risk summary appropriate administration of 2.5% dextrose and 0.45% sodium chloride injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with 2.5% dextrose and 0.45% sodium chloride injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2

United States - English - NLM (National Library of Medicine)

international medication systems, limited - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 50% dextrose injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels.     the solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. slow infusion of hypertonic solutions is essential to ensure proper utilization of dextrose and avoid production of hyperglycemia. a concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated. dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

United States - English - NLM (National Library of Medicine)

hospira, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - dextrose monohydrate 50 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories and sodium chloride. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an additive cap. - mix container contents thoroughly. preparation for admin

United States - English - NLM (National Library of Medicine)

sypharma pty ltd - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - dextrose monohydrate 5 g in 100 ml - sykes 5% dextrose and 0.9% sodium chloride injection is indicated as a source of water and calories for all species.  sykes 5% dextrose and 0.9% sodium chloride injection is contraindicated in patients with a known allergy to corn or corn products.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient. none known. check flexible container solution composition, lot number, and expiry date. do not remove solution container from its overwrap until immediately before use. use sterile equipment and aseptic technique. to open - turn solution container over so that the text is face down. using the pre-cut corner tabs, peel open the overwrap and remove solution container. - check the solution container for leaks by squeezing firmly. if leaks are found, or if the seal is not intact, discard the solution. - do not use if the solution is cloudy or a precipitate is present. to add medication - identify white additive port with arrow pointing toward container. - immediately before injecting additives, break off white additive port cap with the arrow pointing toward container. - hold base of white additi

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose hydrous (unii: lx22yl083g) (dextrose - unii:iy9xdz35w2), sodium chloride (unii: 451w47iq8x) (sodium chloride - unii:451w47iq8x), potassium chloride (unii: 660yq98i10) (potassium chloride - unii:660yq98i10), magnesium chloride (unii: 02f3473h9o) (magnesium chloride - unii:02f3473h9o), sodium gluconate (unii: r6q3791s76) (sodium gluconate - unii:r6q3791s76), sodium acetate (unii: 4550k0sc9b) (sodium acetate - unii:4550k0sc9b) - injection, solution - 5 g in 100 ml - plasma-lyte® 148 and 5% dextrose injection (multiple electrolytes and dextrose injection, type 1, usp) is indicated as a source of water, electrolytes, and calories, or as an alkalinizing agent. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 50% dextrose injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. the solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. a concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated. dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.